The study was conducted on 60 patients with rheumatoid arthritis Phase I-II, in which 30 patients were treated with preparations "PTH1-BCA" and 30 patients were treated with medicine all the "Single operation Funeral parasitic "(PTH2) 1 month course. Study of drug bay PTH1-BCA control mechanism PTH2 be reported as completed member 8g wrapped in plastic soft sphere. Research shows that the average age of patients was 48 +/- 9.82 (study group) and 49 +/- 10.21 (control group). The incidence of rheumatoid arthritis between male/female 17/43 (28,330/0171,66 percent). Results: The studied group reaching good+strong-pass level (A + B): 24/30 patients (80.0 percent)
the one reaching pass+weak level (C + D): 6/30 patients (20.0 percent). Disease group reaching good+strong-pass level (A + B): 23/30 patients (76.7 percent)
the one reaching pass+weak level (C + D): 7/30 patients (23.3 percent). The drug has no effect on the clinical side, did not alter liver function, kidney, erythrocytes, hemoglobin.